AUA 2024: N-803 plus BCG Complete Response Rate in Non Muscle Invasive Bladder Cancer CIS Subjects: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032)
AUA 2024, N-803 plus BCG, Non Muscle Invasive Bladder Cancer (NMIBC), BCG Refractory, QUILT 3032 trial, ANKTIVA, interleukin-15 superagonist (IL-15), BCG-unresponsive high-grade NMIBC.